# Predictive Value of FDG-PET-CT Scans for Patients With Lung Cancer Receiving Concurrent Chemo-Radiation

> **NCT00522639** · PHASE3 · TERMINATED · sponsor: **Maastricht Radiation Oncology** · enrollment: 120 (estimated)

## Conditions studied

- Lung Cancer
- SCLC
- NSCLC

## Interventions

- **OTHER:** 18F-deoxyglucose (FDG)

## Key facts

- **NCT ID:** NCT00522639
- **Lead sponsor:** Maastricht Radiation Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-10
- **Primary completion:** —
- **Final completion:** 2009-06
- **Target enrollment:** 120 (ESTIMATED)
- **Why stopped:** Poor accrual
- **Last updated:** 2009-06-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00522639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00522639, "Predictive Value of FDG-PET-CT Scans for Patients With Lung Cancer Receiving Concurrent Chemo-Radiation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00522639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*